Cybin announces last subject dosed in part b of its phase 1 cyb004-e trial

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the completion of dosing the last subject in part b of its three-part cyb004-e phase 1 trial evaluating intravenous n,n-dimethyltryptamine (“iv dmt”) in healthy volunteers. with the achievement of this milestone, cybin intends.
CYBN Ratings Summary
CYBN Quant Ranking